ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to SEC 300 mg, but failed to show improvement by week 52. https://t.co/EJvoBlW9or https://t.co/tYb1fIA3pw